Table 6. The relationship between pathological indicators and the efficacy of neoadjuvant chemotherapy.

Variables	Assignment	N	PCR n (%)	χ2	P
Her-2				0.214	0.644
	Positive	106	9 (8.5)
	Negative	350	25 (7.1)
Ki-67				9.061	0.003
	Low expression	133	2 (1.5)
	High expression	293	28 (9.6)
	Missing data	30	4 (13.3)
Triple negative				0.638	0.424
	Yes	121	11 (9.1)
	No	335	23 (6.9)
ER				2.600	0.107
	Positive	274	16 (5.8)
	Negative	182	18 (9.9)
PR				3.256	0.071
	Positive	268	15 (5.6)
	Negative	188	19 (10.1)
Pathological molecular types				4.097	0.393
	Luminal A	85	3 (3.5)
	Luminal B1	8	0 (0.0)
	Luminal B2	43	5 (11.6)
	Her-2 positive	106	9 (8.5)
	Triple negative	121	11 (9.1)
	Typing failure	89	6 (6.7)
	Missing data	4	0 (0.0)
Tumor size				3.828	0.148
	≤2cm	131	7 (5.3)
	2–5cm	265	25 (9.4)
	>5cm	60	2 (3.3)
Lymph node metastasis				58.384	0.000
	No	166	33 (19.9)
	Yes	340	1 (0.3)
pTMN Stage				18.772	0.000
	II Stage	207	23 (11.1)
	III/IV Stage	183	1 (0.5)